Eledon Pharmaceuticals (ELDN) Receivables - Other (2018 - 2021)

Eledon Pharmaceuticals (ELDN) has 4 years of Receivables - Other data on file, last reported at $87000.0 in Q2 2021.

• Quarterly Receivables - Other fell 46.3% year-over-year to $87000.0 in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $87000.0 (down 46.3% YoY) and the FY2020 annual result came in at $110000.0, down 55.1% from the prior year.
• Receivables - Other declined to $87000.0 in Q2 2021, from $197000.0 in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $956000.0 in Q3 2019 to a low of $87000.0 in Q2 2021.
• A 4-year average of $390727.3 and a median of $245000.0 in 2019 frame the typical range for Receivables - Other.
• Annual changes were most pronounced in 2020 — Receivables - Other tumbled 78.08% — and 2021, when it retreated 20.24%.
• Tracing ELDN's Receivables - Other over 4 years: stood at $594000.0 in 2018, then tumbled by 58.75% to $245000.0 in 2019, then plunged by 55.1% to $110000.0 in 2020, then decreased by 20.91% to $87000.0 in 2021.
• The last three Receivables - Other figures came in at $87000.0 (Q2 2021), $197000.0 (Q1 2021), and $110000.0 (Q4 2020), per Business Quant data.